Becker's Healthcare September 12, 2019
Maia Anderson

A new study released Sept. 11 explains why so many cancer drugs don’t make it past clinical trials, according to STAT.

Figuring out which genes are essential to cancer cells’ survival and advising drug developers to target those genes is an approach that has led to life-saving drugs like Herceptin.

However, 95 percent of compounds that cure cancer in lab mice fail when they are tested in human clinical trials, according to STAT.

The study, published in Science Translational Medicine, found that five genes previously thought to be critical to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Market Research, Pharma, Precision Medicine, Technology, Trends
Pfizer shifts creative to Publicis in latest marketing move
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours
Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
Understanding the politics of drug pricing in the United States
FDA approves Akebia anemia pill, two years after rejection

Share This Article